111 results on '"Wyant, T"'
Search Results
2. P441 Long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI Programme)
3. Network Analysis and the Possibility of Its Use in Education
4. CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study
5. Vedolizumab as induction and maintenance therapy for ulcerative colitis
6. Applying Network Analysis and Educational Technology to the Teaching of A-V Technicians
7. 1141PD - CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study
8. Phase I Study of the Investigational Anti-Guanylyl Cyclase C (GCC) Antibody-Drug Conjugate (ADC) Mln0264 in Adult Patients with Advanced Gastrointestinal Malignancies Expressing GCC
9. DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies
10. P025 Vedolizumab does not affect the suppressive activity of gut-homing T regulatory cells
11. P592 A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab
12. 329 The Investigational Drug MLN0264 First-in-human, First in Class ADC Targeting GCC: Phase I Dose-escalation Study and Supportive Scientific Rationale
13. 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
14. P019 Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity
15. P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers
16. Operational modelling of preventive maintenance of a production plant
17. The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates.
18. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
19. Regional immunomodulation of the gastrointestinal tract without systemic immunosuppression in Cynomolgus macaques by vedolizumab.
20. P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis
21. P130 - Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α 4β 7 integrin
22. Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrin
23. O-0009 - Phase I Study of the Investigational Anti-Guanylyl Cyclase C (GCC) Antibody-Drug Conjugate (ADC) Mln0264 in Adult Patients with Advanced Gastrointestinal Malignancies Expressing GCC
24. Tqm In Maintenance To Improve Manufacturing Performance
25. MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
26. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.
27. using network analysis on a learning sequence.
28. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.
29. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes.
30. Potent immunoregulatory effects of Salmonella typhi flagella on antigenic stimulation of human peripheral blood mononuclear cells.
31. Posttranslational Changes in Band 3 in Adult and Aging Brain following Treatment with Ergoloid Mesylates, Comparison to Changes Observed in Alzheimer's Disease
32. An integrated approach of maintenance tools and techniques to improve manufacturing performance
33. The oilspill risk analysis model of the U. S. Geological Survey
34. TQM in maintenance to improve manufacturing performance
35. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
36. Oilspill risk analysis for the Western Gulf of Alaska (Kodiak Island) Outer Continental Shelf lease area
37. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.
38. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
39. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
40. A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
41. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.
42. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
43. Safety Culture: Establishing Processes to Support Trust and Accountability for Risk Reduction .
44. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
45. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
46. Partnering to promote safety in the nursing profession.
47. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
48. Be a Leader by Cultivating a Culture of Safety.
49. Recommendations for the development and validation of flow cytometry-based receptor occupancy assays.
50. Role of receptor occupancy assays by flow cytometry in drug development.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.